MabThera/Rituxan

NICE backs Cancer Drugs Fund support for Roche's Gazyvaro

on Roche's MabThera (rituximab) - and as monotherapy for maintenance thereafter - via the CDF. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and safety profile.

Standing out in a crowd

Celltrion’s current focus, he said, is immunology and oncology. With biosimilars of Remicade and Mabthera already approved in Europe, the next in line for a licence is likely to be ... versions of MabThera and Herceptin.

Sandoz joins Europe's MabThera biosimilar push

Novartis' Sandoz unit has become the second company to claim approval in Europe for a biosimilar version of Roche's blockbuster immunotherapy drug MabThera. ... MabThera is celebrating its 20th year on the market this year, and has been a massive earner

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

The CHMP also backed three biosimilars of Roche's Rituxan (rituximab) developed by Celltrion namely Blitzima, Tuxella and Ritemvia.

WHO pilots scheme to make biosimilars available to poorer countries

Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin. ... In the latest move the WHO says it will focus on biosimilar medicines, starting with Roche's widely-used cancer drugs MabThera/Rituxan (rituximab) and

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]